Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Next-Generation Sequencing Approach in Methylation Analysis of HNF1B and GATA4 Genes: Searching for Biomarkers in Ovarian Cancer

I. Bubancova, H. Kovarikova, J. Laco, E. Ruszova, O. Dvorak, V. Palicka, M. Chmelarova,

. 2017 ; 18 (2) : . [pub] 20170222

Language English Country Switzerland

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc17023252

DNA methylation is well-known to be associated with ovarian cancer (OC) and has great potential to serve as a biomarker in monitoring response to therapy and for disease screening. The purpose of this study was to investigate methylation of HNF1B and GATA4 and correlate detected methylation with clinicopathological characteristic of OC patients. The study group consisted of 64 patients with OC and 35 control patients. To determine the most important sites of HNF1B and GATA4, we used next-generation sequencing. For further confirmation of detected methylation of selected regions, we used high-resolution melting analysis and methylation-specific real-time polymerase chain reaction (PCR). Selected regions of HNF1B and GATA4 were completely methylation free in all control samples, whereas methylation-positive pattern was observed in 32.8% (HNF1B) and 45.3% (GATA4) of OC samples. Evaluating both genes together, we were able to detect methylation in 65.6% of OC patients. We observed a statistically significant difference in HNF1B methylation between samples with different stages of OC. We also detected subtype specific methylation in GATA4 and a decrease of methylation in late stages of OC. The combination of unmethylated HNF1B and methylated GATA4 was associated with longer overall survival. In our study, we employed innovative approach of methylation analysis of HNF1B and GATA4 to search for possible epigenetic biomarkers. We confirmed the significance of the HNF1B and GATA4 hypermethylation with emphasis on the need of selecting the most relevant sites for analysis. We suggest selected CpGs to be further examined as a potential positive prognostic factor.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17023252
003      
CZ-PrNML
005      
20170720124146.0
007      
ta
008      
170720s2017 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/ijms18020474 $2 doi
035    __
$a (PubMed)28241454
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Bubancova, Ivana $u Institute of Clinical Biochemistry and Diagnostics, Charles University Faculty of Medicine and University Hospital Hradec Kralove, 500 05 Hradec Kralove, Czech Republic. ivana.bubancova@fnhk.cz.
245    10
$a Next-Generation Sequencing Approach in Methylation Analysis of HNF1B and GATA4 Genes: Searching for Biomarkers in Ovarian Cancer / $c I. Bubancova, H. Kovarikova, J. Laco, E. Ruszova, O. Dvorak, V. Palicka, M. Chmelarova,
520    9_
$a DNA methylation is well-known to be associated with ovarian cancer (OC) and has great potential to serve as a biomarker in monitoring response to therapy and for disease screening. The purpose of this study was to investigate methylation of HNF1B and GATA4 and correlate detected methylation with clinicopathological characteristic of OC patients. The study group consisted of 64 patients with OC and 35 control patients. To determine the most important sites of HNF1B and GATA4, we used next-generation sequencing. For further confirmation of detected methylation of selected regions, we used high-resolution melting analysis and methylation-specific real-time polymerase chain reaction (PCR). Selected regions of HNF1B and GATA4 were completely methylation free in all control samples, whereas methylation-positive pattern was observed in 32.8% (HNF1B) and 45.3% (GATA4) of OC samples. Evaluating both genes together, we were able to detect methylation in 65.6% of OC patients. We observed a statistically significant difference in HNF1B methylation between samples with different stages of OC. We also detected subtype specific methylation in GATA4 and a decrease of methylation in late stages of OC. The combination of unmethylated HNF1B and methylated GATA4 was associated with longer overall survival. In our study, we employed innovative approach of methylation analysis of HNF1B and GATA4 to search for possible epigenetic biomarkers. We confirmed the significance of the HNF1B and GATA4 hypermethylation with emphasis on the need of selecting the most relevant sites for analysis. We suggest selected CpGs to be further examined as a potential positive prognostic factor.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    12
$a nádorové biomarkery $7 D014408
650    12
$a metylace DNA $7 D019175
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a transkripční faktor GATA4 $x genetika $x metabolismus $7 D050991
650    _2
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a hepatocytární jaderný faktor 1-beta $x genetika $x metabolismus $7 D051539
650    _2
$a vysoce účinné nukleotidové sekvenování $7 D059014
650    _2
$a lidé $7 D006801
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a lidé středního věku $7 D008875
650    _2
$a stupeň nádoru $7 D060787
650    _2
$a staging nádorů $7 D009367
650    _2
$a nádory vaječníků $x diagnóza $x genetika $x metabolismus $x mortalita $7 D010051
650    _2
$a prognóza $7 D011379
650    _2
$a promotorové oblasti (genetika) $7 D011401
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kovarikova, Helena $u Institute of Clinical Biochemistry and Diagnostics, Charles University Faculty of Medicine and University Hospital Hradec Kralove, 500 05 Hradec Kralove, Czech Republic. kovarikovahe@lfhk.cuni.cz.
700    1_
$a Laco, Jan $u The Fingerland Department of Pathology, Charles University Faculty of Medicine and University Hospital Hradec Kralove, 500 05 Hradec Kralove, Czech Republic. lacoj@lfhk.cuni.cz.
700    1_
$a Ruszova, Ema $u Department of Clinical Genetics, University Hospital Hradec Kralove, 500 05 Hradec Kralove, Czech Republic. ema.ruszova@fnhk.cz.
700    1_
$a Dvorak, Ondrej $u Department of Obstetrics and Gynecology, Charles University Faculty of Medicine and University Hospital Hradec Kralove, 500 05 Hradec Kralove, Czech Republic. ondrej.dvorak@fnhk.cz.
700    1_
$a Palicka, Vladimir $u Institute of Clinical Biochemistry and Diagnostics, Charles University Faculty of Medicine and University Hospital Hradec Kralove, 500 05 Hradec Kralove, Czech Republic. palicka@lfhk.cuni.cz.
700    1_
$a Chmelarova, Marcela $u Institute of Clinical Biochemistry and Diagnostics, Charles University Faculty of Medicine and University Hospital Hradec Kralove, 500 05 Hradec Kralove, Czech Republic. marcela.chmelarova@fnhk.cz.
773    0_
$w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 18, č. 2 (2017)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28241454 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170720 $b ABA008
991    __
$a 20170720124639 $b ABA008
999    __
$a ok $b bmc $g 1238933 $s 984165
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 18 $c 2 $e 20170222 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
LZP    __
$a Pubmed-20170720

Find record

Citation metrics

Archiving options